Prostate Cancer

Continuous administration of the novel tubulin inhibitor VERU-111 proved to be safe and demonstrated antitumor activity, evidenced by prostate-specific antigen reductions, objective tumor responses, and durable activity, in men with previously treated metastatic castration-resistant prostate cancer.

Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.

Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.

Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.

Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for olaparib for approval as a monotherapy for metastatic castration-resistant prostate cancer and BRCA1/2 mutations who have progressed after previous therapy with a new hormonal agent.

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Ipatasertib combined with abiraterone acetate plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity compared with placebo plus abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer with PTEN loss.

Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

Quoc-Dien Trinh, MD, discusses current strategies on the treatment of patients with high-risk prostate cancer during the COVID-19 crisis.

The combination of nivolumab and ipilimumab demonstrated improved responses in a cohort of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer compared with a cohort of chemotherapy-exposed patients.

Paul L. Nguyen, MD, discusses the utility of adding a brachytherapy boost to radiation therapy in the ASCENDE-RT trial.

Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.

Hemigland high-intensity focused ultrasound ablation of the prostate was found to be a safe and effective primary treatment for men with localized prostate cancer, leading to continence preservation and suitable short-term disease control.

The FDA granted a fast track designation to the highly-selective N-terminal domain inhibitor EPI-7386 for the treatment of adult patients with metastatic castration-resistant prostate cancer who are resistant to standard-of-care options.

Atish D. Choudhury, MD, PhD, discusses clinical trials of interest examining different agents, such as darolutamide, enzalutamide, and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.

Jennifer Cullen, MPH, PhD, discusses the genomic test as a predictor of outcomes in patients with unfavorable intermediate-risk prostate cancer and next steps for research.

The addition of enzalutamide to androgen deprivation therapy (ADT) led to maintained health-related quality of life and low symptom burden versus placebo and ADT in men with metastatic castration-sensitive prostate cancer.

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Huma Q. Rana, MD, MPH, discusses a recent trial aimed to identify how genetic counseling could impact an individual’s decision to undergo genetic testing and ultimately, identify strategies to improve access to this service for men with potentially lethal prostate cancer.

Findings from the phase 3 STAMPEDE, LATITUDE , and TITAN studies, brought to light the utility of second-generation androgen receptor inhibitors.

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.